ALA-101
CD19+ B‑cell lymphomas and leukaemias
PreclinicalActive
Key Facts
About Arovella
Arovella builds off‑the‑shelf CAR‑iNKT cell therapies to deliver multi‑targeted cancer immunotherapy.
View full company profileCD19+ B‑cell lymphomas and leukaemias
Arovella builds off‑the‑shelf CAR‑iNKT cell therapies to deliver multi‑targeted cancer immunotherapy.
View full company profile